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Abstract
The increasing prevalence of hospital and community-acquired infections caused by multidrug-resistant (MDR) bacterial pathogens is rapidly
limiting the options for effective antibiotic therapy. Systematic studies on combinations of already available antibiotics that could provide an
effective treatment against MDR bacteria are needed. We tested combinations of antibiotics that target one important physiological
function (peptidoglycan synthesis) at several steps, and studied Enterobacteriaceae (Klebsiella pneumoniae and Escherichia coli) for which
multidrug resistance associated with ESBL-producing plasmids has become a major problem. To measure the effectiveness of antibiotics
alone and in combination, we used checkerboard assays, static antibiotic concentration time-kill assays, and an improved in-vitro kinetic
model that simulates human pharmacokinetics of multiple simultaneously administered antibiotics. The target strains included an MDR
K. pneumoniae isolate responsible for a recent major hospital outbreak. A double combination (fosfomycin and aztreonam) and a triple
combination (fosfomycin, aztreonam and mecillinam) were both highly effective in reducing bacterial populations in all assays, including the in
vitro kinetic model. These combinations were effective even though each of the MDR strains was resistant to aztreonam alone. Our results
provide an initial validation of the potential usefulness of a combination of antibiotics targeting peptidoglycan synthesis in the treatment of
MDR Gram-negative bacteria. We suggest that a combination of fosfomycin with aztreonam could become a useful treatment option for
such infections and should be further studied.
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Introduction
Access to effective antibiotic chemotherapy is critical to the
success of many life-saving procedures in modern medicine,
including invasive surgery, cancer chemotherapy, transplanta-
tions and the treatment of preterm babies [1]. The global
evolution of multidrug-resistant pathogens, driven by the
overuse and misuse of antibiotics, and coupled with the lack of
new antibiotics in the pipeline [2], could push modern
medicine into a post-antibiotic era.
Major resistance problems are being caused by multi-
drug-resistant (MDR) Gram-negative pathogens [3]. Today,
nosocomial infections caused by Enterobacteriaceae in patients
with underlying diseases are difﬁcult to treat with available
antibiotics and are associated with signiﬁcantly increased
mortality [4]. In part the difﬁculty in treatment is caused by
the prevalence of extended spectrum b-lactamases (ESBL) in
Enterobacteriaceae, compromising the effectiveness of the
b-lactam antibiotics. The most common class of ESBL in
Enterobacteriaceae in Europe is CTX-M-15 [5], usually
encoded on plasmids and spread by horizontal gene transfer.
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Beginning in 2005 an outbreak of a Klebsiella pneumoniae
strain producing the CTX-M-15 ESBL occurred within Uppsala
University Hospital [6], causing major infection problems for
patients [7]. The genetic sequence of the outbreak strain
plasmid showed that it was composed of a pKPN3 K. pneu-
moniae plasmid backbone combined with bla CTX-M-15 encoded
on a multidrug-resistant cassette, probably acquired from the
outbreak Escherichia coli ST131 strain [8]. The clinical relevance
of this isolate, the paucity of treatment options, and the
availability of detailed molecular data on resistance mecha-
nisms, motivated us to study whether effective therapy could
be achieved using combinations of available antibiotics. As
comparator strains we used a fully susceptible E. coli and an
E. coli into which the ESBL plasmid had been conjugated. The
ESBL-producing E. coli was used in this study as a control of
interest as some patients hospitalized during the outbreak
were double infected with an ESBL-producing K. pneumoniae
clone and the acquired E. coli strain.
The use of antibiotics in combination is already a common
hospital procedure in empirical treatment of severe infections
[9], but often guidelines on suitable combinations to use are
sparse. We decided to focus exclusively on antibiotics that
inhibited one major target (peptidoglycan synthesis), the
hypothesis being that targeting one cellular system at multiple
points perturbs it beyond recovery and prevents resistance
formation from single step compensatory mutations (‘The
multi-targeting hypothesis’) [10]. We also wished to include
antibiotics that are not currently widely used, so-called
underused or ‘forgotten antibiotics’ [11], to increase the
potential of ﬁnding novel synergies. Thus, the antibiotics we
concentrated on were fosfomycin, aztreonam and mecillinam.
Both fosfomycin and mecillinam (in the prodrug form of
pivmecillinam) have been used to treat uncomplicated UTIs,
whilst aztreonam has been used to treat complicated
Gram-negative infections in hospitalized patients.
Fosfomycin was our main antibiotic of interest, due to its
potential as a driving force in antibiotic combination therapy.
Fosfomycin displays several interesting pharmacokinetic/phar-
macodynamic aspects, i.e. lack of cross-resistance by its unique
inhibition of UDP-N- acetyleglucosamin-1-carboxyvinyltrans-
ferase [12] and potential to permeabilize bacterial cells to
increase uptake of other antimicrobial agents by acting as a
chelating agent for magnesium in the outer membrane [13].
Furthermore, fosfomycin has been shown to have good activity
against ESBL-producing K. pneumoniae isolates, with 81.3%
reported positive in a recent study [14]. Aztreonam was
selected as a combination partner due to its PBP 3 (and slight
PBP1) inhibiting action and previously reported in-vitro synergy
with fosfomycin against Pseudomonas aeruginosa [13]. Mecilli-
nam was selected due to its low levels of resistance, according
to a recent study [15]where 89% of CTX-M15-producing
E. coli strains were reported susceptible, but also because its
mechanism of action is inhibition of PBP2 in Gram-negative
cells. Thus, the mode of action of mecillinam complements that
of aztreonam, which should minimize cross-resistance due to
single mutations affecting PBP afﬁnity or expression levels.
Many potentially valuable antibiotics are currently not a
therapeutic option in many countries, often because they are
not licensed for human use. We believe studies that
investigate their therapeutic potential, individually or in
combination, can provide support for the political and
economic interests required to motivate the changes that
can make these drugs more widely available to meet
increasingly urgent clinical needs. In the course of this study,
we used checkerboard assays, static antibiotic concentration
time-kill assays, and an improved in-vitro kinetic model that
simulates human pharmacokinetics of multiple simultaneously
administered antibiotics.
Materials and Methods
Bacterial strains and plasmids
Three strains were used in this study (Table 1): (i) DA15000, a
clinical isolate of K. pneumoniae from Uppsala University
Hospital carrying the multi-resistance plasmids pUUH239.1
(5243 bp) and pUUH239.2 (220 824 bp) [8]; (ii) MG1655, an
E. coli K-12 wild-type [16]; and (iii) DA14833, E. coli
MG1655 F-, k-, ilvG, rfb-50, rph-1, nalR, strR/pUUH239.2
(transconjugant). The plasmid pUUH239.2 encodes resistance
to b-lactams (blaCTX-M-15, blaTEM-1 and blaOXA-1), aminoglyco-
sides [aac-(6′)-1b-cr and aadA2], tetracyclines [tet(A) and
tetR], trimethoprim (dhfrXII), sulphonamides (sul1), quater-
nary ammonium compounds (qacED1), macrolides [mph
(A)-mxr-mphR(A)] and the heavy metal ions silver, copper
and arsenic [8]. Bacteria were cultivated in Mueller–Hinton II
broth (MHII), a cation-adjusted broth (Becton, Dickinson and
Company, Sparks, MD, USA) and plated on MHII agar (Difco
Laboratories, Detroit, MI, USA).
TABLE 1. Susceptibility testing and FICI for antibiotic com-
binations
MICa (n=3) FICI (n=3)
FOF ATM MEC
FOF
+ATM
FOF
+MEC
ATM
+MEC
MG1655 8 (S) 0.625 (S) 0.25 (S) 0.33 0.27 0.2
DA14833 16 (S) 64 (R) 1 (S) 0.23 0.22 0.38
DA15000 32 (S) 64 (R) 4 (S) 0.58 0.32 0.50
aS, sensitive; R, resistant; according to EUCAST SIR data.
FICI and MIC data are based on at least three independent assays in each case.
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Antibiotics
Antibiotics (Sigma-Aldrich, Stockholm, Sweden) were dis-
solved in water at 10 mg/mL and stored at 20°C. Stocks
were thawed prior to use and diluted as required. Antibiotics
tested were aztreonam (ATM), fosfomycin (FOF) and mecil-
linam (MEC). Vancomycin was used to validate drug concen-
tration proﬁles in the in vitro kinetic model system.
MIC assays
Minimal inhibitory concentrations (MICs) of antibiotics (mg/L)
were measured by broth dilution in MHII and classiﬁed as
susceptible or resistant in accordance with the European
breakpoint recommendations [17].
Checkerboard FIC testing
The fractional inhibitory concentration index (FICI) of pairwise
antibiotic combinations was measured in 96-well microtitre
plates with two-fold dilution steps. Wells were inoculated with
106 CFU/mL and read after 18 h incubation at 37°C. FICI was
deﬁned as: ∑FIC = FICA + FICB = CAcomb/MICAalone + CBcomb/
MICB
alone, where MICA
alone and MICB
alone are the MICs of the
drugs A and B when acting alone and CA
comb and CB
comb are
the concentrations of the drugs A and B in combination,
respectively, in all of the wells corresponding to an MIC
(isoeffective combinations) [18]. ‘Synergy’ between antibiotics
was deﬁned as FICI ≤ 0.5 [19].
In-vitro static time-kill assays
Bacteria cultivated in MHII broth were inoculated into 15-mL
tubes at a concentration of 108 CFU/mL. Initial antibiotic
concentrations, based on maximal (non-protein bound)
serum concentrations obtained in humans [20–22], were:
ATM, 144 mg/L; MEC, 61 mg/L; FOF, 209 mg/L. The high
bacterial inoculum was used to increase the resolution
between combination therapies at such high drug concen-
trations. Samples were taken at 0, 1, 2, 4, 6 and 24 h and
spread on MHII agar to assess antibacterial effect. To detect
antibiotic carry-over effects, the sample was applied on one
half of the plate and the antibiotic allowed to brieﬂy diffuse
before spreading, and on affected plates the affected area
was not counted. Furthermore, because three dilution steps
were plated, carryover effects could be detected by
discrepancies between the high and lower concentration
samples. Where possible, only plates with between 30 and
300 colonies were counted. The limit of detection was
20 CFU/mL, and measured values below this were set to
zero.
Multidrug in vitro kinetic model
An in-vitro kinetic model previously developed in this labora-
tory [23] can mimic the human pharmacokinetics of one drug.
In order to be able to expose bacteria to up to three
independent pharmacokinetic proﬁles in one individual exper-
iment, we improved the model by connecting two com-
puter-controlled syringe pumps (Syringe Infusion Pump 22,
Harvard Apparatus, Holliston, MA, United States) (Fig. 1).
Antibiotic-free medium is added to the system using a constant
rate peristaltic pump (P-500, Pharmacia, Sweden) and the ﬂow
rate is set to simulate the shortest drug half-life. Bacteria are
retained in the system by a downstream 45-lm ﬁlter. The two
computer-controlled syringes dynamically add antibiotic to
mimic each of the drugs with slower elimination. The syringe
pumps are controlled using the programme ARUDose 2.0
(Antibiotic Research Unit, Department of Medical Sciences,
FIG. 1. A new multidrug in vitro kinetic model. The left panel shows a schematic view of the model set-up simulating the human kinetics of three
drugs independently. The right panel illustrates the logic behind the ARUDose 2.0 control software, which calculates the amount of antibiotic needed
to be added at each time-point to adjust for the quicker dilution rates.
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Uppsala University, Uppsala, Sweden), according to the
following logic:
Amount of drug A at time t:
Ma ¼ M0aekat
Amount of drug B to add at time t:
Mb ¼ M0bekaðtþ1Þ M0bekb t
Amount of drug C to add at time t:
Mc ¼ M0cekaðtþ1Þ M0cekc t
where M = amount of drug in the bottle (mg), M0 = initial
amount (mg), k = rate constant (s1) and t = time (s). This
new system was evaluated for accuracy using vancomycin as
test substance, analysed with an initial drug concentration of
20 mg/L (M0 = 2 mg, 100 mL system volume) at 1, 2 and 4 h
half-lives. To minimize experimental variation, the model ﬂask
was replaced by three identical ﬂasks, and the inlet tubes were
split one to each ﬂask, to enable simultaneous validation of
three half-lives in the system using one single test antibiotic
and quantiﬁcation assay. The model system performed as
expected and correctly simulated the different drug kinetics
(Figure S1). This new kinetic model system was used to
measure the antibacterial effect of drugs and drug combina-
tions on the clinical isolate of K. pneumonia (DA15000). Initial
assay drug concentrations were the Cmax serum concentra-
tions as used in the in-vitro static time-kill assays. Simulated
half-lives were 1.9 h (ATM) [22], 0.85 h (MEC) [20] and 2.2 h
(FOF) [24]. Bacteria were cultivated in MHII broth and samples
were taken at 0, 1, 2, 4, 6 and 8 h and later tested on MHII
agar.
Results
Minimal inhibitory concentrations and checkerboard assays
Minimal inhibitory concentrations (MICs) for E. coli strains
MG1655 and DA14833 and the K. pneumoniae clinical isolate
DA15000 against three ‘forgotten/underused’ antibiotics [11]
that target peptidoglycan synthesis are shown in Table 1.
According to clinical breakpoints [17], DA14833 and
DA15000, carrying pUUH239.2, were resistant to aztreonam
(ATM) but susceptible to mecillinam (MEC) and fosfomycin.
MG1655 was susceptible to all three antibiotics.
In a classic checkerboard assay against wild-type E. coli
MG1655 and the MDR E. coli DA14833 all pairwise combina-
tions of the three antibiotics (FOF, ATM and MEC) exhibited
synergy against both E. coli strains with ∑FICI’s ranging from
0.2 to 0.38 (Table 1). Against the K. pneumoniae strain, two of
three pairwise combinations were synergistic, and the
FOF-ATM combination was by a close margin classed as
additive (FICI 0.58, n=3).
In-vitro static antibiotic concentration time-kill assays
Static antibiotic concentration time-kill assays were performed
with ATM, MEC and FOF on MG1655, DA14833 and DA15000,
testing each antibiotic alone and in combination with FOF.With
the exception of FOF alone, all therapies were effective against
MG1655 (Fig. 2a). Only the combination therapies were
effective against the transconjugant E. coli DA14833 (Fig. 2b).
Only two combination therapies, FOF+ATM and FOF+ATM+
MEC, were effective against the K. pneumoniae clinical isolate
DA15000, and reduced the population by at least ﬁve log units
(Fig. 1c), with the triple combination being slightly more
effective than the double (0.5 log difference at 24 h). Killing
data, including standard deviations, are shown in Tables S1–S3.
Multidrug in-vitro kinetic model
Based on the positive outcome from the static concentration
assays we decided to test DA15000 in the newly developed
multidrug in vitro kinetic model that mimics human pharmaco-
kinetics and supports multiple concurrent concentration
proﬁles. We tested FOF alone, FOF+ATM and the triple
combination, FOF+ATM+MEC. The bacterial inoculum was
108 CFU/mL, and a single dose of antibiotic was applied at
serum Cmax. FOF alone allowed regrowth but the double
combination of FOF+ATM reduced the population by c. 4 log
units in 6 h (Fig. 3). The triple combination, FOF+ATM+MEC,
was more effective than the double (FOF+ATM), achieving c. 4
log units of kill by 6 h, and yielding a smaller bacterial load;
each time-point had consistently lower cell concentrations
than double or single therapy (FOF). In each case there was
evidence of some regrowth from 6 to 8 h, where all three
antibiotics were below their respective MIC.
Discussion
We have shown that the combinations FOF+ATM and
FOF+ATM+MEC are effective in reducing the population of
multidrug-resistant ESBL K. pneumoniae at clinically relevant
drug concentrations, in static experiments at Cmax and in a
newly developed model simulating human pharmacokinetics.
Interestingly, the FOF+ATM combination has earlier been
reported to show an effect against MDR Pseudomonas aerugin-
osa, but was only tested in an in vitro assay using static drug
concentrations [13]. ATM signiﬁcantly increases the killing
effect although the strain is clinically resistant to ATM alone
(Table 1). In general, combination therapy performed better
than single therapy against all strains. This is especially clear in
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the case of mecillinam, where poor kill and signiﬁcant
regrowth occurred even at 619 and ~159 MIC against
transconjugant E. coli and the K. pneumonia strain, respectively.
This can partly be explained by the inoculum effect, due to the
enzymatic nature of resistance-conveying beta-lactamases,
since higher inoculum was used in the time-kills as compared
with the checkerboards and MIC assays. Additionally, it is
becoming more evident that static endpoint-based assays such
as MIC tests and checkerboards correlate poorly with static
(a)
(b)
FIG. 3. Drug combinations assayed in the extended in vitro kinetic
model. Time-kill curves are shown in panel (a) where drugs were
diluted at rates mimicking human pharmacokinetics. The vertical
arrows indicate the time at which the concentration of each drug was
diluted to its MIC. In panel (b) drug concentration curves as a function
of time, and strain MIC, are shown. The target strain, DA1500, is an
MDR clinical isolate of K. pneumoniae. Symbols: X (growth control);
closed triangle (FOF); open square (FOF+ATM); open circle
(FOF+ATM+MEC). All data points are the mean of three independent
experiments with standard deviations shown.
(a)
(b)
(c)
FIG. 2. Static antibiotic-concentration time-kill assays. Time-kill data
as a function of drug or drug combination for three strains: (a)
MG1655; (b) DA14833; (c) DA15000. Symbols: X (growth control);
closed triangle (FOF); closed square (ATM); closed circle (MEC); open
square (FOF+ATM); open triangle (FOF+MEC); open circle
(FOF+ATM+MEC). All data points are the mean of three independent
experiments. To avoid excessive clutter standard deviations are not
shown in the ﬁgure (available in Tables S1–S3).
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and dynamic time-kill results [25], where much more infor-
mation about the antibiotic interaction over the whole time
course is captured; our results further emphasize this
discrepancy.
The in vitro kinetic model data clearly show an increased
rate of kill and corresponding reduction of cell concentration
by each added antibiotic. We interpret this as follows: even
though concentrations well above MIC are used, and pepti-
doglycan synthesis therefore is highly perturbed by even a
single treatment, there is still potential to increase the effect by
targeting the synthesis pathway at several points. Additionally,
the cell wall permeabilizing effect of fosfomycin could increase
uptake of the other drugs, as well as reduce the effects of
membrane porins and efﬂux systems. More studies are needed
to elucidate the mechanism of the interaction between these
drug combinations.
In this study we used the standard initial dosing as normally
applied with the individual drugs. Our motivation was that such
dosing levels are already approved from a safety perspective. As
can be seen in Fig. 3, this resulted in drug pharmacokinetics
where the time above MIC varied from 2.2 to 6 h between the
different substances. Even so, the combination was effective and
only when the concentration of all three drugs went below MIC
did the surviving bacteria show signs of regrowth (Fig. 3).
Accordingly, we suggest that future studies could be directed
towards testing non-standard initial doses of these drugs, such
that the double or triple combination therapy is maintained
throughout the dosing period. It is worth noting that the effects
of redosing are not addressed in this study, and are of
considerable interest for future investigations. In view of the
serious lack of novel antibiotics in clinical development, there is a
need for a systematic testing of combinations of existing
antibiotics that may be useful against currently problematic
resistant infections. Such testing needs to include older and
‘forgotten’ antibiotics [9] because few therapeutic options are
left. However, in many parts of the world one or more of these
antibiotics are unavailable [11]. There may be great value in
re-evaluating and making these ‘forgotten antibiotics’ available, so
that they becomemorewidely available for use in clinical therapy.
In the evaluation of the potential of antibiotic combinations,
it is critical that account is taken of the pharmacokinetics of
the drug. When comparing time-kill experiments with end-
point-based checkerboard assay, eight of nine of the check-
erboard tests were synergistic. This corresponds well with the
time-kill results, except for mecillinam as noted earlier.
However, there was no obvious correlation between the
level of synergy and the effect measured in the time kill
experiments.
We have successfully improved a previously developed in
vitro kinetic model in order to be able to mimic the
pharmacokinetics of up to three different simultaneously
administered antibiotics. In our study, there was a consistency
between the static time-kill assays and the kinetic assays in
the current experiments. However, it may not always be the
case that static and kinetic assays will provide consistent data,
and in our opinion results from in vitro combination studies
using static concentrations need to be validated using models
simulating human pharmacokinetics such as the kinetic model
described here. Small animal models cannot adequately
provide this effective simulation of human half-lives, and
may also be too expensive for systematic evaluations of
combinations against multiple strains. Judicious use of antibi-
otic combinations based on thorough empirical studies may
be a way to manage infections caused by multiresistant
bacteria.
In summary, our results provide a further indication of the
potential usefulness of a combination of antibiotics targeting
peptidoglycan synthesis in the treatment of MDR Gram-neg-
ative bacteria, especially K. pneumoniae. We suggest that a
combination of fosfomycin with aztreonam, possibly in com-
bination with mecillinam, could become a useful treatment
option for such infections and should be further studied.
Acknowledgements
We thank Crystle Cotingting for her assistance in testing the
improved in vitro kinetic model system.
Funding
This work was supported by grants to OC and DH from the
Swedish Foundation for Strategic Research (SSF) and the
Swedish Innovation Agency (Vinnova), and from the Swedish
Research Council (Vetenskapsrådet) and the EU 7th Frame-
work Programme (PAR Project) to DH.
Transparency Declaration
The authors declare no conﬂicts of interest.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Validation of the new extended in vitro kinetic
model system using vancomycin.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O267–O273
O272 Clinical Microbiology and Infection, Volume 20 Number 4, April 2014 CMI
Tables S1–S3. Mean CFU at 0, 6 and 24 h during static
time-kill assays.
References
1. Cars O, Hedin A, Heddini A. The global need for effective antibiot-
ics-moving towards concerted action. Drug Resist Updat 2011; 14: 68–69.
2. Freire-Moran L, Aronsson B, Manz C et al. Critical shortage of new
antibiotics in development against multidrug-resistant bacteria-time to
react is now. Drug Resist Updat 2011; 14: 118–124.
3. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new
antibiotic resistance mechanism in india, pakistan, and the uk: a
molecular, biological, and epidemiological study. Lancet Infect Dis 2010;
10: 597–602.
4. Kang CI, Chung DR, Ko KS, Peck KR, Song JH. Risk factors for
infection and treatment outcome of extended-spectrum beta-lactam-
ase-producing escherichia coli and klebsiella pneumoniae bacteremia in
patients with hematologic malignancy. Ann Hematol 2012; 91: 115–121.
5. Bush K, Fisher JF. Epidemiological expansion, structural studies, and
clinical challenges of new beta-lactamases from gram-negative bacteria.
Annu Rev Microbiol 2011; 65: 455–478.
6. Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus ASA. The
ﬁrst major extended-spectrum beta-lactamase outbreak in scandinavia
was caused by clonal spread of a multiresistant klebsiella pneumoniae
producing ctx-m-15. APMIS 2008; 116: 302–308.
7. Lytsy B, Lindback J, Torell E, Sylvan S, Velicko I, Melhus A. A
case-control study of risk factors for urinary acquisition of klebsiella
pneumoniae producing ctx-m-15 in an outbreak situation in sweden.
Scand J Infect Dis 2010; 42: 439–444.
8. Sandegren L, Linkevicius M, Lytsy B, Melhus A, Andersson DI. Transfer
of an escherichia coli st131 multiresistance cassette has created a
klebsiella pneumoniae-speciﬁc plasmid associated with a major noso-
comial outbreak. J Antimicrob Chemother 2012; 67: 74–83.
9. Mouton JW, Ambrose PG, Canton R et al.Conserving antibiotics for the
future: new ways to use old and new drugs from a pharmacokinetic and
pharmacodynamic perspective. Drug Resist Updat 2011; 14: 107–117.
10. Silver LL, Bostian KA. Discovery and development of new antibiotics:
the problem of antibiotic resistance. Antimicrob Agents Chemother 1993;
37: 377–383.
11. Pulcini C, Bush K, Craig WA et al. Forgotten antibiotics: an inventory
in europe, the united states, canada, and australia. Clin Infect Dis 2012;
54: 268–274.
12. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME.
Synergy of fosfomycin with other antibiotics for gram-positive and
gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359–368.
13. Okazaki M, Suzuki K, Asano N et al. Effectiveness of fosfomycin
combined with other antimicrobial agents against multidrug-resistant
pseudomonas aeruginosa isolates using the efﬁcacy time index assay. J
Infect Chemother 2002; 8: 37–42.
14. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE.
Fosfomycin for the treatment of multidrug-resistant, including
extended-spectrum beta-lactamase producing, enterobacteriaceae
infections: a systematic review. Lancet Infect Dis 2010; 10: 43–50.
15. Titelman E, Iversen A, Kahlmeter G, Giske CG. Antimicrobial
susceptibility to parenteral and oral agents in a largely polyclonal
collection of ctx-m-14 and ctx-m-15-producing escherichia coli and
klebsiella pneumoniae. APMIS 2011; 119: 853–863.
16. Blattner FR, Plunkett G 3rd, Bloch CA et al. The complete genome
sequence of escherichia coli k-12. Science 1997; 277: 1453–1474.
17. EUCAST. Breakpoint tables for interpretation of mics and zone diameters.
Version 1.1 April 2010: electronic publication, 2010. Available from
http://www.eucast.org (last accessed 2 December 2010).
18. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Deﬁning fractional
inhibitory concentration index cutoffs for additive interactions based
on self-drug additive combinations, monte carlo simulation analysis,
and in vitro-in vivo correlation data for antifungal drug combinations
against aspergillus fumigatus. Antimicrob Agents Chemother 2010; 54:
602–609.
19. Odds FC. Synergy, antagonism, and what the chequerboard puts
between them. J Antimicrob Chemother 2003; 52: 1.
20. Gambertoglio JG, Barriere SL, Lin ET, Conte JE Jr. Pharmacokinetics of
mecillinam in health subjects. Antimicrob Agents Chemother 1980; 18:
952–956.
21. Goto M, Sugiyama M, Nakajima S, Yamashina H. Fosfomycin kinetics
after intravenous and oral administration to human volunteers.
Antimicrob Agents Chemother 1981; 20: 393–397.
22. Wong SL, Sorgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL. Lack
of pharmacokinetic drug interactions following concomitant adminis-
tration of telavancin with aztreonam or piperacillin/tazobactam in
healthy participants. J Clin Pharmacol 2009; 49: 816–823.
23. L€owdin E, Odenholt I, Bengtsson S, Cars O. Pharmacodynamic effects
of sub-mics of benzylpenicillin against streptococcus pyogenes in a
newly developed in vitro kinetic model. Antimicrob Agents Chemother
1996; 40: 2478–2482.
24. Frossard M, Joukhadar C, Erovic BM et al. Distribution and antimicro-
bial activity of fosfomycin in the interstitial ﬂuid of human soft tissues.
Antimicrob Agents Chemother 2000; 44: 2728–2732.
25. Sopirala MM, Mangino JE, Gebreyes WA et al. Synergy testing by etest,
microdilution checkerboard, and time-kill methods for pan-drug-resis-
tant acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54:
4678–4683.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O267–O273
CMI Hickman et al. Antibiotic combinations for MDR Gram-negatives O273
